

# Percutaneous Patent Foramen Ovale (PFO) Closure

Guideline Number: MMG171.A  
 Effective Date: May 1, 2020

[Instructions for Use](#)

Table of Contents	Page
<a href="#">Coverage Rationale</a> .....	1
<a href="#">Documentation Requirements</a> .....	1
<a href="#">Applicable Codes</a> .....	2
<a href="#">Description of Services</a> .....	2
<a href="#">Clinical Evidence</a> .....	2
<a href="#">U.S. Food and Drug Administration</a> .....	4
<a href="#">References</a> .....	4
<a href="#">Guideline History/Revision Information</a> .....	6
<a href="#">Instructions for Use</a> .....	6

Related Medical Management Guideline
<ul style="list-style-type: none"> <li><a href="#">Omnibus Codes</a></li> </ul>

## Coverage Rationale

Note: This policy does not apply to individuals <18 years of age.

Percutaneous patent foramen ovale closure for the prevention of recurrent ischemic stroke is proven and medically necessary when used according to [U.S. Food and Drug Administration \(FDA\)](#) labeled indications, contraindications, warnings and precautions and all of the following criteria are met:

- History of cryptogenic stroke confirmed by imaging; and
- A cardiologist and a neurologist agree that the stroke is likely embolic in nature; and
- Other causes of ischemic stroke have been ruled out including, but not limited to, carotid disease, hypercoagulable states or atrial fibrillation; and
- Individual is 18–60 years of age.

Due to insufficient evidence of efficacy, percutaneous patent foramen ovale closure is unproven and not medically necessary for all other stroke or related neurological indications including, but not limited to, primary prevention of stroke, transient ischemic attacks, and migraine prevention.

## Documentation Requirements

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The documentation requirements outlined below are used to assess whether the member meets the clinical criteria for coverage but do not guarantee coverage of the service requested.

Required Clinical Information
<b>Percutaneous Patent Foramen Ovale (PFO) Closure</b> Medical notes documenting all of the following: <ul style="list-style-type: none"> <li>• History and co-morbid medical condition(s)</li> <li>• Documentation of member’s symptoms</li> <li>• Complete report(s) of diagnostic imaging (MRI, CT scan, x-rays)</li> </ul>

## Required Clinical Information

### Percutaneous Patent Foramen Ovale (PFO) Closure

- Results of diagnostic testing performed to rule out other causes including, but not limited to, carotid disease, hypercoagulable states or atrial fibrillation
- Documentation of an evaluation by a cardiologist and a neurologist and both are in agreement that the stroke is likely embolic in nature

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this guideline does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
93580	Percutaneous transcatheter closure of congenital interatrial communication (i.e., Fontan fenestration, atrial septal defect) with implant

*CPT® is a registered trademark of the American Medical Association*

## Description of Services

A stroke occurs when there is a loss of blood flow to the brain causing damage and tissue death. There are two types of stroke: ischemic and hemorrhagic. An ischemic stroke is caused by a blood clot that blocks a blood vessel in the brain. A hemorrhagic stroke is caused by a blood vessel that breaks and bleeds into the brain. A cryptogenic stroke is a type of ischemic stroke in which a specific cause is not found. In some individuals, the cause of a cryptogenic stroke may be due to a patent foramen ovale (PFO). A transient ischemic attack (TIA) occurs when the blood supply to the brain is blocked or interrupted for a short period of time but causes no permanent damage.

A PFO is a normal opening in the heart that is present in all people during fetal development. The opening is in the septal wall separating the left and right atria of the heart. Typically, this opening closes on its own after birth, but in some cases, the opening remains opened throughout adulthood. For the majority of people with a PFO, the condition does not cause any problems and requires no treatment (American Academy of Neurology, 2016). However, in some people with a PFO, small blood clots that form in the peripheral venous system may cross from the right to the left circulation and cause ischemic stroke if they reach the cerebral arterial circulation. Prevention of recurrent cryptogenic stroke in people with a PFO may be achieved through antithrombotic/anticoagulation therapy, surgery or percutaneous closure. While surgery is theoretically one treatment option, it is rarely used for this indication due to the inherent risks of surgery. Additionally, surgery has not been studied in comparison to percutaneous closure.

Percutaneous or transcatheter PFO closure devices use catheter technology to access the heart and close the PFO without the need for open-heart surgery and cardiopulmonary bypass. Once in place, the device prevents blood, and potentially blood clots, from flowing between the heart's right and left atria.

## Clinical Evidence

A systematic review and meta-analysis of randomized controlled trials compared the safety and efficacy of percutaneous PFO closure (with medical therapy) versus medical therapy alone in patients with cryptogenic stroke or TIA. Among 3627 patients, 1829 were allocated to PFO closure and 1798 to medical treatment. The mean follow-up was 3.7 years. Results showed a significant reduction in ischemic stroke recurrence using the two currently FDA approved PFO closure devices. One study using the older STARFlex device showed no improvement. Combined data across all studies showed no significant reduction in all-cause mortality or TIA. New-onset atrial fibrillation occurred more frequently (five-fold) in the PFO group but resolved in 72% of cases within 45 days (Ntaios et al., 2018).

The following studies were included in the review:

- CLOSE (Mas et al., 2017) – used several PFO closure devices including the two currently FDA approved devices.
- REDUCE (Søndergaard et al., 2017) – Gore® Helex® (product discontinued) or Gore® Cardioform Septal Occluder
- RESPECT-LT (Saver et al., 2017) – Amplatzer™ PFO Occluder
- PC Trial (Meier et al., 2013) – Amplatzer™ PFO Occluder
- CLOSURE I (Furlan et al., 2012) – STARFlex (no longer on the market)

Two other meta-analyses reached similar conclusions (Garg et al., 2018; Turc et al., 2018).

In a small randomized controlled trial (DEFENSE-PFO) published after the Ntaois et al. (2018) meta-analysis, Lee et al. (2018) reported that device closure in addition to medical therapy prevented secondary stroke events following cryptogenic stroke in patients with high-risk PFO. High-risk PFO was defined as PFO with atrial septal aneurysm, hypermobility or PFO size  $\geq 2$  mm. ClinicalTrials.gov number NCT01550588.

A Hayes report concluded that there is some evidence that PFO closure is associated with a lower risk of recurrent stroke or other cerebrovascular events than that seen with medical therapy alone. However, the report is less definitive in its conclusions as it included older devices no longer on the market and showed less benefit (Hayes, 2018).

A NICE report concluded that evidence on the safety of percutaneous PFO closure to prevent recurrent cerebral embolic events shows serious but infrequent complications. Evidence on its efficacy is adequate (NICE, 2013).

## Migraine Prevention

The evidence is insufficient to support the use of PFO closure for treating migraines. Several randomized trials have failed to reach their primary endpoint of cessation or reduction in migraine days.

In the PREMIUM study, Tobis et al. (2017) randomly assigned patients who had a PFO and medically intractable migraine with or without aura to undergo closure with the Amplatzer PFO Occluder (n=123) or a sham procedure (n=107). Both groups also received medical therapy. The procedure was generally safe, with only one device-related serious adverse event occurring during 1 year of follow-up. There was no difference between the groups in the percentage of responders (primary efficacy endpoint), defined as those having at least a 50% reduction in migraine attacks per month in months 10 through 12 after randomization. However, the PFO closure group had a lower mean number of headache days per month.

In the multicentre, prospective, randomized, open-label, international PRIMA trial, Mattle et al. (2016) investigated the effect of percutaneous PFO closure in patients with migraines refractory to medical treatment. Participants were randomized to PFO closure using the Amplatzer PFO Occluder (n=53) or medical treatment (n=54). The primary endpoint was reduction in monthly migraine days during months 9-12 after randomization compared with a 3-month baseline phase. The trial was terminated prematurely because of slow enrollment. Eighty-three patients (40 occluder, 43 control) completed 12-month follow-up. Mean migraine days at baseline were 8 ( $\pm 4.7$  SD) in the closure group and 8.3 ( $\pm 2.4$ ) in controls. Findings on the primary endpoint were inconclusive with -2.9 days after PFO closure versus -1.7 days in control group. In patients with refractory migraine with aura and PFO, closure did not reduce overall monthly migraine days.

A NICE report concluded that evidence on the efficacy of percutaneous PFO closure for recurrent migraine is inadequate in quality and quantity. The evidence on safety shows a small incidence of well-recognized but sometimes serious adverse events, including device embolization and device prolapse (each reported in less than 1% of patients) (NICE, 2010).

In the MIST study, Dowson et al. (2009) evaluated the effectiveness of PFO closure to resolve refractory migraine headache. One hundred forty-seven patients were randomized to transcatheter PFO closure with the STARFlex implant (n=74) or to a sham procedure (n=73). Patients were followed up for 6 months. The primary efficacy end point was cessation of migraine headache 91 to 180 days after the procedure. No significant difference was observed in the primary end point of migraine headache cessation between implant and sham groups (3 of 74 versus 3 of 73, respectively). Secondary end points also were not achieved.

## Professional Societies

### *American Academy of Neurology (AAN)*

An AAN practice advisory states that clinicians should not routinely offer percutaneous PFO closure to patients with cryptogenic ischemic stroke outside of a research setting (Level R). In rare circumstances, such as recurrent strokes despite adequate medical therapy with no other mechanism identified, clinicians may offer the AMPLATZER PFO Occluder if it is available (Level C) (Messé et al., 2016). (The evidence base for this practice advisory does not include recently published studies.)

### *American Heart Association/American Stroke Association (AHA/ASA)*

The AHA/ASA guidelines for the prevention of stroke in patients with stroke and TIA (Kernan et al., 2014) make the following recommendations regarding PFO closure:

- For patients with an ischemic stroke or TIA and a PFO who are not undergoing anticoagulation therapy, antiplatelet therapy is recommended
- For patients with an ischemic stroke or TIA and both a PFO and a venous source of embolism, anticoagulation is indicated depending on stroke characteristics. When anticoagulation is contraindicated, an inferior vena cava filter is reasonable
- For patients with a cryptogenic ischemic stroke or TIA and a PFO without evidence for deep vein thrombosis, available data does not support a benefit for PFO closure
- In the setting of PFO and deep vein thrombosis, PFO closure by a transcatheter device might be considered, depending on the risk of recurrent deep vein thrombosis

(The evidence base for these guidelines does not include recently published studies.)

## U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Transcatheter PFO closure is a procedure and, therefore, is not subject to FDA regulation. However, the devices designed for PFO occlusion are subject to FDA regulation. These devices are regulated by the premarket approval process and are classified as transcatheter septal occluders (product code MLV).

The Amplatzer™ PFO Occluder (SJM/Abbott) received FDA premarket approval (P120021) on October 28, 2016. The device is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke. Additional information is available at:

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120021>. Accessed January 3, 2020.

The Gore® Cardioform Septal Occluder (W.L. Gore) received FDA premarket approval (P050006/S060) on July 31, 2017. The device is indicated for the percutaneous, transcatheter closure of the following defects of the atrial septum:

- Ostium secundum atrial septal defects
- PFO to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke.

Additional information is available at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P050006S060>. Accessed January 3, 2020.

## References

American Academy of Neurology (AAN). Practice Advisory update of Practice Parameter: Recurrent stroke with patent foramen ovale. Patient summary. July 2016.

Dowson A, Mullen MJ, Peatfield R, et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex

septal repair implant to resolve refractory migraine headache. *Circulation*. 2008 Mar 18;117(11):1397-404. Erratum in: *Circulation*. 2009 Sep 1;120(9):e71-2.

Furlan AJ, Reisman M, Massaro J, et al.; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. *N Engl J Med*. 2012 Mar 15;366(11):991-9.

Garg L, Haleem A, Varade S, et al. Patent foramen ovale closure in the setting of cryptogenic stroke: a meta-analysis of five randomized trials. *J Stroke Cerebrovasc Dis*. 2018 Sep;27(9):2484-2493.

Hayes, Inc. Comparative Effectiveness Review. Transcatheter closure of patent foramen ovale for prevention of recurrent cryptogenic stroke. Lansdale, PA: Hayes, Inc.; May 2018. Updated June 2019.

Kernan WN, Ovbiagele B, Black HR, et al.; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014 Jul;45(7):2160-236. Erratum in: *Stroke*. 2015 Feb;46(2):e54.

Kuijpers T, Spencer FA, Siemieniuk RAC, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. *BMJ*. 2018 Jul 25;362:k2515.

Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. *J Am Coll Cardiol*. 2018 May 22;71(20):2335-2342.

Mas JL, Derumeaux G, Guillon B, et al.; CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. *N Engl J Med*. 2017 Sep 14;377(11):1011-1021.

Mattle HP, Evers S, Hildick-Smith D, et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. *Eur Heart J*. 2016 Jul 7;37(26):2029-36.

Meier B, Kalesan B, Mattle HP, et al.; PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. *N Engl J Med*. 2013 Mar 21;368(12):1083-91.

Messé SR, Gronseth G, Kent DM, et al. Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2016 Aug 23;87(8):815-21.

National Institute for Health and Care Excellence (NICE). Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events. IPG 472. December 2013.

National Institute for Health and Care Excellence (NICE). Percutaneous closure of patent foramen ovale for recurrent migraine. IPG 370. December 2010.

Ntaios G, Papavasileiou V, Sagris D, et al. Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack: updated systematic review and meta-analysis. *Stroke*. 2018 Feb;49(2):412-418.

Saver JL, Carroll JD, Thaler DE, et al.; RESPECT Investigators. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. *N Engl J Med*. 2017 Sep 14;377(11):1022-1032.

Søndergaard L, Kasner SE, Rhodes JF, et al.; Gore REDUCE Clinical Study Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. *N Engl J Med*. 2017 Sep 14;377(11):1033-1042.

Tobis JM, Charles A, Silberstein SD, et al. Percutaneous closure of patent foramen ovale in patients with migraine: the PREMIUM trial. *J Am Coll Cardiol*. 2017 Dec 5;70(22):2766-2774.

Turc G, Calvet D, Guérin P, et al.; CLOSE Investigators. Closure, anticoagulation, or antiplatelet therapy for cryptogenic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE study. *J Am Heart Assoc*. 2018 Jun 17;7(12). pii: e008356.

Wiktor DM, Carroll JD. The case for selective patent foramen ovale closure after cryptogenic stroke. *Circ Cardiovasc Interv*. 2018 Mar;11(3):e004152.

## Guideline History/Revision Information

Date	Summary of Changes
01/01/2021	<b>Template Update</b> <ul style="list-style-type: none"><li>Reformatted policy; transferred content to new template</li></ul>
05/01/2020	<ul style="list-style-type: none"><li>New Medical Management Guideline</li></ul>

## Instructions for Use

This Medical Management Guideline provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this guideline, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Management Guideline is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare West Medical Management Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Member benefit coverage and limitations may vary based on the member's benefit plan Health Plan coverage provided by or through UnitedHealthcare of California, UnitedHealthcare Benefits Plan of California, UnitedHealthcare of Oklahoma, Inc., UnitedHealthcare of Oregon, Inc., UnitedHealthcare Benefits of Texas, Inc., or UnitedHealthcare of Washington, Inc.